Role of the MMP9 gene in hemorrhagic transformations after tissue-type plasminogen activator treatment in stroke patients

Stroke

Volumn 43, Issue 5, 2012, Pages 1398-1400

  Fernández Cadenas, Israel ^a   Del Río Espínola, Alberto ^a   Carrera, Caty ^a   Domingues Montanari, Sophie ^a   Mendióroz, Maite ^a   Delgado, Pilar ^a   Rosell, Anna ^a   Ribó, Marc ^a   Giralt, Dolors ^a   Quintana, Manolo ^a   Castellanos, Mar ^b   Obach, Victor ^c   Martínez, Sergi ^d   Freijo, Mari Mar ^d   Jiménez Conde, Jordi ^f   Roquer, Jaume ^f   Martí Fábregas, Joan ^e   Molina, Carlos A ^a   Alvarez Sabín, José ^a   Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL DE BASURTO   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Genetics; Tissue type plasminogen activator

Indexed keywords

ALTEPLASE; GELATINASE B; RNA;

AGED; ARTICLE; BLEEDING; BLOOD SAMPLING; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

AGED; AGED, 80 AND OVER; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RNA, MESSENGER; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84860225029     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.639823     Document Type: Article

References (10)

1. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. (Pubitemid 46138121)
2. Lichtman JH, Watanabe E, Allen NB, Jones SB, Dostal J, Goldstein LB. Hospital arrival time and intravenous tPA use in US Academic Medical Centers, 2001-2004. Stroke. 2009;40:3845-3850.
3. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107: 598-603. (Pubitemid 36176811)
4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study(ECASS). JAMA. 1995;274:1017-1025.
5. Shimajiri S, Arima N, Tanimoto A, Murata Y, Hamada T, Wang KY, et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 1999;455:70-74. (Pubitemid 29322784)
6. González-Conejero R, Fernández-Cadenas I, Iniesta JA, Marti-Fabregas J, Obach V, Alvarez-Sabín J, et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke. 2006;37:2288-2293. (Pubitemid 44337171)
7. Montaner J, Fernández-Cadenas I, Molina CA, Monasterio J, Arenillas JF, Ribó M, et al. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke. 2003; 34:2851-2855. (Pubitemid 37517755)
8. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.
9. Rosell A, Cuadrado E, Ortega-Aznar A, Hernández-Guillamon M, Lo EH, Montaner J. MMP9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke. 2008;39:1121-1126. (Pubitemid 351440679)
10. Cuadrado E, Ortega L, Hernández-Guillamon M, Penalba A, Fernández-Cadenas I, Rosell A, et al. Tissue plasminogen activator (tPA) promotes neutrophil degranulation and MMP9 release. J Leukoc Biol. 2008;84: 207-214. (Pubitemid 351960296)